MARKET

ZVRA

ZVRA

Zevra Therapeutics Inc
NASDAQ
12.07
+0.05
+0.42%
Opening 13:05 07/11 EDT
OPEN
12.05
PREV CLOSE
12.02
HIGH
12.20
LOW
11.89
VOLUME
436.98K
TURNOVER
--
52 WEEK HIGH
12.37
52 WEEK LOW
4.270
MARKET CAP
659.98M
P/E (TTM)
-6.3654
1D
5D
1M
3M
1Y
5Y
1D
Zevra Therapeutics announces presentations on MIPLYFFA at NNPDF conference
TipRanks · 7h ago
Zevra Therapeutics Announces MIPLYFFA® (arimoclomol) Featured in Presentations at the National Niemann Pick Disease Foundation Conference
Barchart · 12h ago
Zevra Therapeutics Is Maintained at Overweight by Cantor Fitzgerald
Dow Jones · 1d ago
Cantor Fitzgerald Maintains Overweight on Zevra Therapeutics, Raises Price Target to $29
Benzinga · 1d ago
Zevra Therapeutics price target raised to $29 from $25 at Cantor Fitzgerald
TipRanks · 1d ago
Analysts Offer Insights on Healthcare Companies: Zevra Therapeutics (ZVRA), Exact Sciences (EXAS) and GH Research (GHRS)
TipRanks · 1d ago
Zevra Therapeutics, Inc.'s (NASDAQ:ZVRA) 26% Jump Shows Its Popularity With Investors
Simply Wall St · 1d ago
Noteworthy Monday Option Activity: ZVRA, U, WNS
NASDAQ · 3d ago
More
About ZVRA
Zevra Therapeutics, Inc. is a commercial-stage rare disease company combining science, data, and patient need to create transformational therapies for diseases with limited or no treatment options. It has a diverse portfolio of products and product candidates, which includes pre-clinical, clinical, and commercial stage assets. Its active commercial products and development assets include MIPLYFFA, OLPRUVA, Celiprolol, KP1077IH, KP1077N and AZSTARYS. MIPLYFFA (arimoclomol) is its approved therapy for the treatment of Niemann-Pick disease type C (NPC). OLPRUVA (sodium phenylbutyrate) is its treatment for the treatment of certain urea cycle disorders (UCDs). Celiprolol is its investigational clinical candidate for the treatment of Vascular Ehlers-Danlos Syndrome (VEDS). KP1077 is its product candidate intended for the treatment of rare sleep disorders. KP1077N is a clinical development candidate for narcolepsy. AZSTARYS is for the treatment of attention deficit and hyperactivity disorder.

Webull offers Zevra Therapeutics Inc stock information, including NASDAQ: ZVRA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ZVRA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ZVRA stock methods without spending real money on the virtual paper trading platform.